Previous close | 66.76 |
Open | 66.95 |
Bid | 66.93 x 900 |
Ask | 67.04 x 300 |
Day's range | 66.74 - 67.56 |
52-week range | 65.90 - 87.87 |
Volume | |
Avg. volume | 7,228,700 |
Market cap | 83.485B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 14.88 |
EPS (TTM) | 4.50 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 3.08 (4.60%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 84.04 |
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.